


Attorney Docket No. P-144-US2  
Application Serial No.: 10/691,094  
Page 2 of 6

### Complete Listing of the Claims

This listing of the claims will replace all prior versions, and listings of claims in the application.

1-21. (canceled)

22. (currently amended) A method of treating a condition responsive to a tyrosine kinase inhibitor, wherein the condition is ~~a proliferative disorder~~ selected from acute myeloid leukemia, small cell lung cancer, prostate cancer, gastrointestinal cancer, breast cancer, brain cancer, and restenosis, the method comprising administering to a patient in need of treatment a therapeutically-effective amount of a compound of formula (Ia):



(Ia)

wherein R is hydrogen, methyl, or ethyl;

or a pharmaceutically-acceptable salt thereof.

23. (previously presented) The method of Claim 22, wherein the compound is selected from the group consisting of:

3-[3,5-dimethyl-4-(3-oxo-3-piperazin-1-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one,

3-[3,5-dimethyl-4-[3-oxo-3-(4-ethyl)piperazin-1-ylpropyl]-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one,

and pharmaceutically-acceptable salts thereof.


**BEST AVAILABLE COPY**

Attorney Docket No. P-144-US2  
Application Serial No.: 10/691,094  
Page 3 of 6

24. (previously presented) The method of Claim 22 wherein the compound is 3-[3,5-dimethyl-4-(3-oxo-3-piperazin-1-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one or a pharmaceutically-acceptable salt thereof.

25-27. (canceled)

28. (currently amended) A method of treating a condition responsive to a tyrosine kinase inhibitor, wherein the condition is a proliferative disorder selected from acute myeloid leukemia, small cell lung cancer, prostate cancer, gastrointestinal cancer, breast cancer, brain cancer, and restenosis, the method comprising administering to a patient in need of treatment a therapeutically-effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a compound of formula (Ia):



(Ia)

wherein R is hydrogen, methyl, or ethyl,  
or a pharmaceutically-acceptable salt thereof.

29. (previously presented) The method of Claim 28, wherein the compound is selected from the group consisting of:

3-[3,5-dimethyl-4-(3-oxo-3-piperazin-1-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one,

3-[3,5-dimethyl-4-[3-oxo-3-(4-ethyl)piperazin-1-ylpropyl]-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one,

and pharmaceutically-acceptable salts thereof.

**BEST AVAILABLE COPY**

Attorney Docket No. P-144-US2  
Application Serial No.: 10/691,094  
Page 4 of 6

30. (previously presented) The method of Claim 28 wherein the compound is 3-[3,5-dimethyl-4-(3-oxo-3-piperazin-1-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one or a pharmaceutically-acceptable salt thereof.

31-33. (canceled)

**BEST AVAILABLE COPY**